Generic Drug Sales Grew 22 Percent In 2006 Driven By Unbranded Zocor, Plavix
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Teva's simvastatin were $911 million, and sales of Apotex's clopidogrel were $902 million, according to IMS Health data.
You may also be interested in...
Global Oncology Drug Sales Growth Is Highest Among Top 10 Treatment Classes
Oncology, lipid lowering and respiratory drugs helped to fuel 7 percent sales growth in the global pharmaceutical market in 2006, IMS reports.
Global Oncology Drug Sales Growth Is Highest Among Top 10 Treatment Classes
Oncology, lipid lowering and respiratory drugs helped to fuel 7 percent sales growth in the global pharmaceutical market in 2006, IMS reports.
Judge Rules Against Plavix Recall Based On Sanofi/Bristol’s Settlement Negotiations
Provisions included in a Plavix patent infringement settlement agreement between Sanofi-Aventis/Bristol-Myers Squibb and Apotex "foresaw the possibility that Apotex would launch a generic product and prohibited Sanofi from seeking injunctive relief for a specific period of time after the launch occurred," Manhattan Federal Judge Sidney Stein said in an Aug. 31 ruling, refusing to grant a recall of generic clopidogrel